On Monday, January 26, Morris & Dickson announced the successful completion of the acquisition of Prodigy Health. Effective immediately, Prodigy Health employees will become part of the Morris & Dickson family. Financial terms of the deal were not disclosed.
Established in 2001 in Austin, Texas, Prodigy Health is a specialty pharmaceutical distribution and services company.
Founded in 1841 and headquartered in Shreveport, Louisiana, Morris & Dickson is an independent full-line and specialty pharmaceutical distributor serving health systems, independent pharmacies, clinics, infusion centers and alternative care facilities nationwide. The company combines next-day delivery, automated distribution and a broad pharmaceutical portfolio to support care across the United States.
As part of the transaction, Morris & Dickson will begin a phased integration process using a structured transition services model consistent with industry-specific best practices and applicable regulatory requirements. Prodigy Health will operate as ProdigyMD, a Morris & Dickson company.
Prodigy Health customers and manufacturers will benefit from expanded capabilities without disruption. For customers, this means uninterrupted ordering, fulfillment and support while Morris & Dickson works to integrate Prodigy Health’s plasma and specialty tools to make them available to its broader customer base. For manufacturers, this transaction expands access to a broader, independent distribution platform with the scale and specialty focus required to support complex therapies.
According to data captured in the LevinPro HC database, this transaction marks the third healthcare product distributor acquisition announced in 2026, so far. Liss Capital Partners and Asker Healthcare Group have also made acquisitions in the space this year. There were 37 healthcare product distributor deals announced throughout all of 2025, and 30 announced in 2024.
